Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 11;83(2):263-265.
doi: 10.1136/ard-2023-223955.

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

Chuan Fu Yap  1 , Nisha Nair  1   2 , Annick de Vries  3 , Floris C Loeff  3 , Ann W Morgan  4   5   6 , John D Isaacs  7   8 , Anthony G Wilson  9 , Kimme L Hyrich  2   10 , Anne Barton  1   2 , Darren Plant  11
Affiliations

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

Chuan Fu Yap et al. Ann Rheum Dis. .
No abstract available

Keywords: Adalimumab; Arthritis, Rheumatoid; Autoantibodies; Methotrexate.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AWM is supported National Institute for Health and Care Research (NIHR) and Medical Research Council (MRC). AWM has acted as consultant for Roche/Chugai, Vifor and AstraZeneca. AWM is member of speakers’ bureaus for Roche/Chugai. AWM is on Data Safety Monitoring Board for GSK and Regeneron/Sanofi. AWM is on the board for MRC and Vasculitis UK. KH has received grant/research support from Pfizer, Bristol Myers Squibb (BMS). KH has received honoraria for speaking at educational meeting by Abbvie. AB is supported by the NIHR Manchester Biomedical Research Centre. AB has received grant/research support from Pfizer, BMS, Scipher Medicine and Galapagos (paid to host institution). AB is member of speakers’ bureaus for Galapagos (paid to host institution). DP has received grant/research support from BMS, Versus Arthritis and European Commission.

Figures

Figure 1
Figure 1
(A, C) Kaplan-Meier (KM) plot showing rate of drug antidrug antibody development, stratified by the number of HLA alleles carried (A, HLA-DQA1*03; C, HLA-DRB1*04). The tables presented underneath the KM plots represents the number of participants at risk over time. Blue, orange and green indicate 0, 1 and 2 copies of the alleles respectively. (B, D) Kaplan-Meier plot of drug immunogenicity rate for carriers of at least one copy of HLA-DQA1*03 and HLA-DRB1*04, respectively, for different types of csDMARD cotherapy. Solid line and darkest shade of colour represent cotherapy with MTX, dashed line and middle shade represents non-MTX csDMARD, dotted line with the lightest shade represents monotherapy with only adalimumab. csDMARD, conventional synthetic disease modifying antirheumatic drug; MTX, methotrexate.
See this image and copyright information in PMC

References

    1. Jani M, Chinoy H, Warren RB, et al. . Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015;67:2011–9. 10.1002/art.39169 - DOI - PMC - PubMed
    1. Billiet T, Vande Casteele N, Van Stappen T, et al. . Immunogenicity to Infliximab is associated with HLA-Drb1. Gut 2015;64:1344–5. 10.1136/gutjnl-2015-309698 - DOI - PubMed
    1. Sazonovs A, Kennedy NA, Moutsianas L, et al. . HLA-Dqa1*05 carriage associated with development of anti-drug antibodies to Infliximab and Adalimumab in patients with Crohn's disease. Gastroenterology 2020;158:189–99. 10.1053/j.gastro.2019.09.041 - DOI - PubMed
    1. Liu M, Degner J, Davis JW, et al. . Identification of HLA-Drb1 Association to Adalimumab Immunogenicity. PLoS One 2018;13:e0195325. 10.1371/journal.pone.0195325 - DOI - PMC - PubMed
    1. Rogers AR, Huff C. Linkage disequilibrium between Loci with unknown phase. Genetics 2009;182:839–44. 10.1534/genetics.108.093153 - DOI - PMC - PubMed